Wedbush Reiterates Outperform on Ascendis Pharma, Maintains $327 Price Target
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsReiterationPrice Target
Wedbush analyst Yun Zhong reiterates Ascendis Pharma (NASDAQ:ASND) with a Outperform and maintains $327 price target.
Wedbush analyst Yun Zhong reiterates Ascendis Pharma (NASDAQ:ASND) with a Outperform and maintains $327 price target.